Conference Reports

Denver, Colorado,
29 October 2017 - 02 November 2017
Singapore
20 October 2017 - 21 October 2017
Singapore
06 October 2017 - 08 October 2017
Barcelona
26 August 2017 - 30 August 2017
Singapore
13 July 2017 - 15 July 2017
San Diego, California, US
09 June 2017 - 13 June 2017
Washington, DC
19 May 2017 - 24 May 2017
Houston, Texas, US
22 February 2017 - 24 February 2017
12 November 2016 - 16 November 2016
Yangon
14 October 2016 - 16 October 2016
Rome
27 August 2016 - 31 August 2016
Mexico City
04 June 2016 - 07 June 2016
New Orleans, Louisiana
10 June 2016 - 14 June 2016
London
29 August 2015 - 02 September 2015
Barcelona
30 August 2014 - 09 September 2014
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
Even small risk reductions achieved with improved air quality afford health benefits similar to that gained with smoking and systolic hypertension control, according to a study in an urban China population.
25 May 2017
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
6 days ago
The degree of left atrial (LA) remodeling predicts atrial tachycardia (AT) recurrence rather than atrial fibrillation (AF) recurrence following catheter ablation of AF, a recent study has shown.
24 Apr 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and inflammation in patients with arthritis, but the vascular effects of some NSAIDs have cast doubt on whether they can be used in patients at risk for cardiovascular (CV) disease. At the American Heart Association’s Scientific Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs nonselective NSAIDs.